Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KDM6B | O15054 | 1/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.43 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30843332 | 0.85 | L3MBTL1 (0.68) | NAALAD2L3MBTL1ALDH1A1LMNAKDM6B | |
| SCHEMBL1285620 | 0.85 | L3MBTL1 (0.68) | NAALAD2L3MBTL1ALDH1A1LMNAKDM6B | |
| SCHEMBL2435857 | 0.77 | CA12 (0.51) | NAALAD2L3MBTL1ALDH1A1LMNAKDM6B | |
| SCHEMBL21776362 | 0.77 | L3MBTL1 (0.48) | NAALAD2L3MBTL1ALDH1A1LMNAKDM6B | |
| SCHEMBL20665298 | 0.77 | L3MBTL1 (0.48) | NAALAD2L3MBTL1ALDH1A1LMNAKDM6B | |
| SCHEMBL12892226 | 0.77 | KDM6B (0.50) | NAALAD2L3MBTL1ALDH1A1LMNAKDM6B | |
| SCHEMBL17024865 | 0.75 | NAALAD2 (0.51) | NAALAD2L3MBTL1ALDH1A1LMNAKDM6B | |
| SCHEMBL4127134 | 0.74 | CA12 (0.71) | NAALAD2L3MBTL1ALDH1A1LMNAKDM6B | |
| SCHEMBL22815120 | 0.74 | LMNA (0.44) | ALDH1A1LMNATSHR | |
| SCHEMBL13780257 | 0.73 | L3MBTL1 (0.62) | NAALAD2L3MBTL1ALDH1A1LMNAKDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| CN-114585637-B | MASP-inhibitory compounds and uses thereof | 拜耳公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| CN-114585637-A | MASP inhibiting compounds and uses thereof | 拜耳公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3966226-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-12 | — | — | US | disclosed |
| WO-2020225095-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-12 | — | — | WO | disclosed |
| EP-3194419-B1 | 3-NITROGEN OR SULPHUR SUBSTITUTED OESTRA-1,3,5(10),16-TETRAENE AKR1C3 INHIBITORS | Bayer Pharma AG (DE) | 2018-09-05 | — | — | EP | disclosed |
| US-20170260226-A1 | 3-NITROGEN OR SULPHUR SUBSTITUTED OESTRA-1,3,5(10),16-TETRAENE AKR1C3 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-14 | — | — | US | disclosed |
| EP-3194419-A1 | 3-NITROGEN OR SULPHUR SUBSTITUTED OESTRA-1,3,5(10),16-TETRAENE AKR1C3 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016037956-A1 | 3-NITROGEN OR SULPHUR SUBSTITUTED OESTRA-1,3,5(10),16-TETRAENE AKR1C3 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-17 | — | — | WO | disclosed |
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-09-22 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| WO-2010011302-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011302-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | NAALAD2 222/4885L3MBTL1 960/4885ALDH1A1 2138/4885 |
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, MAOA | NAALAD2 742/4885L3MBTL1 3465/4885ALDH1A1 1158/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | NAALAD2 222/4885L3MBTL1 960/4885ALDH1A1 2138/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | NAALAD2 222/4885L3MBTL1 960/4885ALDH1A1 2138/4885 |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | NAALAD2 222/4885L3MBTL1 960/4885ALDH1A1 2138/4885 |
| US-20170260226-A1 | 3-NITROGEN OR SULPHUR SUBSTITUTED OESTRA-1,3,5(10),16-TETRAENE AKR1C3 INHIBITORS | AKR1C3, AKR1A1, AKR1C1 | NAALAD2 2983/4885L3MBTL1 4783/4885ALDH1A1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.